Evidence map›Paper›PMID 41381800›Full record

ArticleTargeted oncology2026

Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy.

Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Cristina Natha, Rachel Mortan, Rohan Ahuja, Jarrett Rong, Tanvi Gupta, Irene Jeong-Ah Lee, Varun Vemulapalli and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Carolina Colli CruzDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.
Maria Julia Moura Nascimento SantosDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.
Sharada WaliDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.
Cristina NathaDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Rachel MortanDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Rohan AhujaDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Jarrett RongDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Tanvi GuptaDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Irene Jeong-Ah LeeDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Varun VemulapalliDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Sean NgoDepartment of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX, USA.
Kei TakigawaDepartment of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.
Krishnavathana VaratharajaluDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.
Karen C KimDepartment Medicine, Stanford School of Medicine, San Jose, CA, USA.
Kathryn BollinDepartment of Hematology and Oncology, Scripps Cancer Center, San Diego, CA, USA.
Stephane ChampiatDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mehnaz A ShafiDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.
Anusha S ThomasDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA.
Yinghong WangDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX, 77030, USA. ywang59@mdanderson.org.ORCID http://orcid.org/0000-0002-5148-6130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune-mediated gastroenteritis (IMG) has been commonly managed with proton pump inhibitors (PPIs), though their effectiveness is unclear. Histological analysis has shown depletion of parietal cells in the gastric mucosa during IMG, which inhibits PPI action.

objectiveExtending on a small cohort study, we assessed the role of PPIs, and alternatives such as corticosteroids, for managing IMG. PATIENTS AND

methodsThis was a retrospective study at a tertiary care cancer center, including patients with malignancy who received an immune-checkpoint inhibitor (ICI) between 2010 and 2024 and developed IMG.

resultsA total of 399 patients were included, of whom 281 (70.4%) received PD-1/PD-L1 inhibitors. Of these, 190 (47.6%) had exclusive IMG, and 69 (36.3%) were treated with PPIs. PPI use did not significantly impact clinical outcomes. In contrast, 156 (39.1%) received corticosteroids, showing improved clinical outcomes (75.8% vs 65%; p = 0.027) and a trend towards faster symptom resolution (41.5 vs 53 days; p = 0.064). Endoscopic remission was achieved in 71.1% of the steroid group and 36.7% of the non-steroid group. ICI discontinuation was more frequent with steroids (73.5% vs 50.7%; p < 0.0001), as was symptom recurrence within 6 months (16.7% vs 3.6%; p < 0.0001). All-cause mortality was higher in the non-steroid group (51.5% vs 41%; p = 0.042), which had a shorter follow-up period (0.7 vs 1.1 years; p = 0.004). Binary logistic regression showed that steroid use (OR 1.7, 95% CI 1.06-2.7; p = 0.027) and ICI discontinuation (OR 1.9, 95% CI 1.1-3.0; p = 0.007) were associated with clinical improvement.

conclusionOur findings show faster clinical improvement and higher endoscopic remission rates with steroids, while PPIs demonstrated no significant effectiveness.

Indexed as

GastroenteritisImmune Checkpoint InhibitorsImmunotherapyNeoplasmsProton Pump InhibitorsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesImmune Checkpoint InhibitorsProton Pump Inhibitors

Identifiers

PMID41381800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.